ILIzabela Laczmanska

Izabela Laczmanska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Izabela Laczmanska has a total of 176 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A tumour-first molecular diagnostic strategy combining MMR/MSI testing and germline NGS improves risk stratification for lynch syndrome in colorectal and endometrial cancer

    by Paulina Lawicka, Dagmara Michalowska, Marcin Jedryka, Pawel Karpinski, Anna Doraczynska-Kowalik, Marek Bebenek, Agnieszka Chrusciel, Dorota Blomka, Ewelina Czykalko, Mariola Abrahamowska, et al.

  • Open Access

    Gene Expression Signatures in Endometriosis: Molecular Insights and Potential Clinical Applications

    by Marek Murawski, Julia Bania, Izabela Łaczmańska

    Endometriosis (EM) is a chronic disease affecting approximately 190 million women worldwide. Despite its high prevalence and substantial impact on quality of life and fertility, diagnosis remains challenging because of heterogeneous clinical presentation and the lack of validated molecular biomarkers. Altered gene expression provides valuable insights into the molecular mechanisms and biological heterogeneity of EM and may facilitate the identification of candidate biomarkers. However, molecular signatures derived from surgically collected lesions must be distinguished from markers measurable in minimally invasive specimens, as their potential clinical applications differ substantially. This narrative review summarizes current evidence on gene-expression alterations with potential diagnostic and clinical relevance in EM, including differentially expressed genes (DEGs), transcription factors (TFs), genes involved in major pathogenic pathways, and multigene diagnostic models. Among individual candidates, AEBP1, KLF2, HOXB6, and RORB have demonstrated promising discriminatory performance, while HOXB6 may also contribute to distinguishing stages of disease. Distinct expression profiles have also been associated with EM-related infertility. Multigene approaches appear particularly promising, as integrated expression signatures may provide more robust discriminatory performance than individual markers. However, most proposed biomarkers remain at the candidate stage, and methodological and clinical heterogeneity limits comparability across studies. Future research should prioritize independent validation in large, well-characterized cohorts, standardized analytical procedures, and evaluation of multigene signatures in minimally invasive samples to support their clinical translation.

  • Open Access

    Dopaminergic Dysregulation in Migraine: From Hypothalamic A11 Dysfunction to a Systemic Biobehavioral Phenotype

    by Jakub Przegrałek, Filip Targosiński, Karol Marschollek, Izabela Łaczmańska, Lanfranco Pellesi, Sławomir Budrewicz, Marta Nowakowska-Kotas, Marta Waliszewska-Prosół

    Beyond the well-established roles of serotonin and calcitonin gene-related peptide (CGRP), the contribution of dopamine (DA) to migraine pathophysiology remains a subject of intense investigation. DA acts as a neuromodulator, functioning both as a homeostatic pain filter and a driver of premonitory and autonomic symptoms. This review provides a comprehensive synthesis of DA’s involvement in migraine, proposing an integrated model that spans from molecular signaling to a systemic phenotype. A comprehensive search of the PubMed database (1976–2026) was performed. The analysis evaluates data across receptor signaling, hypothalamic connectivity (specifically the A11 nucleus), genetic susceptibility markers and advanced neuroimaging studies. Current evidence identifies dopamine as a gatekeeper of the trigeminovascular threshold, with the hypothalamic A11 nucleus serving as a modulatory hub. Within this circuit, DA exerts concentration-dependent effects: high-affinity D2 receptor activation promotes antinociception, whereas low-affinity D1-like receptors facilitate nociceptive signaling. Clinically, this manifests as a “dopaminergic phenotype” characterized by yawning, nausea, and reward-system dysfunction. This phenotype extends beyond migraine, showing links to comorbidities such as restless legs syndrome (RLS) and attention-deficit/hyperactivity disorder (ADHD). DA’s role in migraine is state-dependent and interconnected with CGRP and serotonergic pathways. Recognizing the dopaminergic phenotype is essential for capturing the clinical heterogeneity of the disorder and may pave the way for personalized, mechanism-based therapeutic strategies.

  • Open Access

    Targeting BRAF in cancers – from molecular diagnostics to personalized therapy

    by Zuzanna Pyc, Rafal Rygiel, Dagmara Michalowska, Marcin Ekiert, Izabela Laczmanska

    Molecular profiling has become a cornerstone of cancer diagnosis and treatment, with BRAF alterations serving as significant markers across various tumor types. The gene encodes a serine/threonine kinase involved in the MAPK/ERK signaling pathway, which regulates cell proliferation and survival. Mutations in BRAF, notably the V600 codon substitutions, are among the most common genetic drivers in melanoma and other cancers, including thyroid, colorectal, and non-small cell lung cancer. BRAF mutations are categorized into three functional classes (class I–III), each with distinct activation mechanisms and therapeutic implications. Current targeted therapies – primarily BRAF and MEK inhibitors, including the first FDA-approved anti-BRAF tumor-agnostic therapy – are most effective in cancers harboring the class I V600E mutation. However, the emergence of resistance to BRAF inhibitors has driven the development of next-generation inhibitors and combination treatments. Furthermore, innovative immunotherapy-based treatments have demonstrated synergistic potential in specific BRAF-mutated malignancies. Accurate molecular diagnostics are crucial in cancer treatment; therefore, numerous molecular diagnostic methods are employed, including next-generation sequencing (NGS), quantitative PCR, droplet digital PCR, Sanger sequencing, and fluorescence in situ hybridi­zation (FISH). NGS, particularly comprehensive genomic profiling, provides the broadest and most detailed genetic data, although simpler laboratory techniques remain popular due to their accessibility and straightforward protocols. Further research into resistance mechanisms and combination therapies, as well as the integration of circulating tumor DNA (ctDNA) in diagnostics, is needed to fully realize the potential of personalized treatment in BRAF-driven tumors.


  • Open Access

    Human iPSC-Derived Muscle Cells as a New Model for Investigation of EDMD1 Pathogenesis

    by Marta Lisowska, Marta Rowińska, Aleksandra Suszyńska, Claudia Bearzi, Izabela Łaczmańska, Julia Hanusek, Amanda Kunik, Volha Dzianisava, Ryszard Rzepecki, Magdalena Machowska, et al.

    Emery–Dreifuss muscular dystrophy type 1 (EDMD1) is a rare genetic disease caused by mutations in the EMD gene, which encodes the nuclear envelope protein emerin. Despite understanding the genetic basis of the disease, the molecular mechanism underlying muscle and cardiac pathogenesis remains elusive. Progress is restricted by the limited availability of patient-derived samples; therefore, there is an urgent need for human-specific cellular models. In this study, we present the generation and characterization of induced pluripotent stem cell (iPSC) lines derived from EDMD1 patients carrying EMD mutations that lead to truncated or absent emerin, together with iPSCs from healthy donor. The patient-specific iPSCs exhibit stable karyotypes, maintain appropriate morphology, express pluripotency markers, and demonstrate the ability to differentiate into three germ layers. To model EDMD1, these iPSCs were differentiated into myogenic progenitors, myoblasts, and multinucleated myotubes, which represent all stages of myogenesis. Each developmental stage was validated by the presence of stage-specific markers, ensuring the accuracy of the model. We present the first iPSC-based in vitro platform that captures the complexity of EDMD1 pathogenesis during myogenesis. This model can significantly contribute to understanding disease mechanisms and develop the targeted therapeutic strategies for EDMD1.


  • Open Access

    Human iPSC-derived muscle cells as a new model for investigation of EDMD1 pathogenesis

    by Marta Lisowska, Marta Rowińska, Aleksandra Suszyńska, Claudia Bearzi, Izabela Łaczmańska, Julia Hanusek, Amanda Kunik, Volha Dzianisava, Ryszard Rzepecki, Magdalena Machowska, et al.

    Emery-Dreifuss muscular dystrophy type 1 (EDMD1) is a rare genetic disease caused by mutations in the EMD gene, which encodes the nuclear envelope protein emerin. Despite understanding the genetic basis of the disease, the molecular mechanism underlying muscle and cardiac pathogenesis remains elusive. Progress is restricted by the limited availability of patient-derived samples, therefore there is an urgent need for human-specific cellular models. In this study, we present the generation and characterization of induced pluripotent stem cell (iPSC) lines derived from EDMD1 patients carrying EMD mutations that lead to truncated or absent emerin, together with iPSCs from healthy donor. The patient-specific iPSCs exhibit stable karyotypes, maintain appropriate morphology, express pluripotency markers and demonstrate the ability to differentiate into three germ layers. To model EDMD1, these iPSCs were differentiated into myogenic progenitors, myoblasts and multinucleated myotubes, which represent all stages of myogenesis. Each developmental stage was validated by the presence of stage-specific markers, ensuring the accuracy of the model. We present the first iPSC-based in vitro platform that captures the complexity of EDMD1 pathogenesis during myogenesis. This model can significantly contribute to understanding disease mechanisms and develop the targeted therapeutic strategies for EDMD1.


  • Open Access

    TYK2 Protein Expression and Its Potential as a Tissue-Based Biomarker for the Diagnosis of Colorectal Cancer

    by Łukasz Zadka, Adam Ustaszewski, Natalia Glatzel-Plucińska, Agnieszka Rusak, Izabela Łaczmańska, Katarzyna Ratajczak-Wielgomas, Alicja Kmiecik, Aleksandra Piotrowska, Katarzyna Haczkiewicz-Leśniak, Agnieszka Gomułkiewicz, et al.

    Background/Objectives: The aim of this study was to examine the expression of TYK2 in colorectal cancer (CRC) and to determine the potential diagnostic and prognostic significance of this kinase. Methods: Digital image analysis was performed to assess immunohistochemical TYK2 reactivity. Results: There were significant differences for all positive pixels between CRC and normal colonic mucosa, with higher TYK2 expression levels observed in surgical margins than in adenocarcinomas (p = 0.0004). Paired t tests showed elevated immunoreactivity for overall TYK2 expression in matched pairs of CRC with adjacent surgical margins (p < 0.0001). Higher percentages of weak (p < 0.0001) and strong pixels (p = 0.0260) were detected in normal colonic mucosa than in cancer tissues. To distinguish cancer from normal intestinal mucosa, the following cutoffs for the TYK2 immune score were found: 29.5% for all cases and 31% for matched pairs. Tumor budding (Bd) was negatively correlated with the percentage of strong pixels for TYK2 (ρ = −0.270, p = 0.0096). The percentage of strong pixels was significantly elevated for the T parameter (p = 0.0428). There was a positive correlation between the number of involved lymph nodes and weak pixels (ρ = 0.239, p = 0.0242). Immunofluorescence staining showed significantly higher signal intensities in colonic mucosa than in CRC. The protein level of TYK2 was significantly higher in controls than in cancer tissues. TEM imaging showed lower levels of TYK2 in cancer than in ulcerative colitis. Conclusions: TYK2 protein expression may bring diagnostic value in patients diagnosed with CRC.

  • Open Access

    Correction to: The analysis of transcriptomic signature of TNBC—searching for the potential RNA‑based predictive biomarkers to determine the chemotherapy sensitivity

    by Stanislaw Supplitt, Pawel Karpinski, Maria Sasiadek, Lukasz Laczmanski, Dorota Kujawa, Rafal Matkowski, Piotr Kasprzak, Mariola Abrahamowska, Adam Maciejczyk, Ewelina Iwaneczko, et al.

  • Open Access

    The analysis of transcriptomic signature of TNBC—searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity

    by Stanislaw Supplitt, Pawel Karpinski, Maria Sasiadek, Lukasz Laczmanski, Dorota Kujawa, Rafal Matkowski, Piotr Kasprzak, Mariola Abrahamowska, Adam Maciejczyk, Ewelina Iwaneczko, et al.

    Neoadjuvant chemotherapy is the foundation treatment for triple-negative breast cancer (TNBC) and frequently results in pathological complete response (pCR). However, there are large differences in clinical response and survival after neoadjuvant chemotherapy of TNBC patients. The aim was to identify genes whose expression significantly associates with the efficacy of neoadjuvant chemotherapy in patients with TNBC. Transcriptomes of 46 formalin-fixed paraffin-embedded (FFPE) tumor samples from TNBC patients were analyzed by RNA-seq by comparing 26 TNBCs with pCR versus 20 TNBCs with pathological partial remission (pPR). Subsequently, we narrowed down the list of genes to those that strongly correlated with drug sensitivity of 63 breast cancer cell lines based on Dependency Map Consortium data re-analysis. Furthermore, the list of genes was limited to those presenting specific expression in breast tumor cells as revealed in three large published single-cell RNA-seq breast cancer datasets. Finally, we analyzed which of the selected genes were significantly associated with overall survival (OS) in TNBC TCGA dataset. A total of 105 genes were significantly differentially expressed in comparison between pPR versus pCR. As revealed by PLSR analysis in breast cancer cell lines, out of 105 deregulated genes, 42 were associated with sensitivity to docetaxel, doxorubicin, paclitaxel, and/or cyclophosphamide. We found that 24 out of 42 sensitivity-associated genes displayed intermediate or strong expression in breast malignant cells using single-cell RNAseq re-analysis. Finally, 10 out of 24 genes were significantly associated with overall survival in TNBC TCGA dataset. Our RNA-seq-based findings suggest that there might be transcriptomic signature consisted of 24 genes specifically expressed in tumor malignant cells for predicting neoadjuvant response in FFPE samples from TNBC patients prior to treatment initiation. Additionally, nine out of 24 genes were potential survival predictors in TNBC. This group of 24 genes should be further investigated for its potential to be translated into a predictive test(s).


  • Open Access

    The analysis of transcriptomic signature of TNBC – searching for the potential RNA-based predictive biomarkers to determine the chemotherapy sensitivity

    by Stanislaw Supplitt, Pawel Karpinski, Maria Sasiadek, Lukasz Laczmanski, Dorota Kujawa, Rafal Matkowski, Piotr Kasprzak, Mariola Abrahamowska, Adam Maciejczyk, Ewelina Iwaneczko, et al.

    Background Neoadjuvant chemotherapy is the foundation treatment for triple-negative breast cancer (TNBC) and frequently results in pathological complete response (pCR). However, there are large differences in clinical response and survival after neoadjuvant chemotherapy of TNBC patients. The aim was to identify genes which expression significantly associates with the efficacy of neoadjuvant chemotherapy in patients with TNBC. Methods Transcriptomes of 46 Formalin-Fixed Paraffin-Embedded (FFPE) tumor samples from TNBC patients were analyzed by RNA-seq by comparing 26 TNBCs with pCR versus 20 TNBCs with pathological partial remission (pPR). Subsequently, we narrowed down the list of genes to those that strongly correlated with drug sensitivity of 63 breast cancer cell lines based on Dependency Map Consortium data re-analysis. Furthermore, the list of genes was limited to those presenting specific expression in breast tumor cells as revealed in three large published single cell RNA-seq breast cancer datasets. Finally, we analyzed which of selected genes were significantly associated with overall survival (OS) in TNBC TCGA dataset. Results A total of 105 genes were significantly differentially expressed in comparison between pPR versus pCR. As revealed by PLSR analysis in breast cancer cell lines out of 105 deregulated genes 42 were associated with sensitivity to docetaxel, doxorubicin, paclitaxel and/or cyclophosphamide. We found that 24 out of 42 sensitivity-associated genes displayed intermediate or strong expression in breast malignant cells using single cell RNAseq re-analysis. Finally, 10 out of 24 genes were significantly associated with overall survival in TNBC TCGA dataset. Conclusion Our RNA-seq based findings suggest that there might be transcriptomic signature consisted of 24 genes specifically expressed in tumor malignant cells for predicting neoadjuvant response in FFPE samples from TNBC patients prior to treatment initiation. Additionally, 9 out of 24 genes were potential survival predictors in TNBC. This group of 24 genes should be further investigated for its potential to be translated into a predictive test(s).